EL7.AI
StocksMedium•17 September 2026•
2 min read

Nuvation Bio Wins Early FDA Approval for Updated IBTROZI Lung Cancer Label

Key Facts

1The US FDA approved a supplemental New Drug Application for IBTROZI to update the duration of response data for NSCLC patients.
2The updated label reflects a median duration of response of nearly 50 months in TKI-naïve patients.
3The approval was granted four months ahead of the scheduled PDUFA date.

In a move that underscores the rapid pace of regulatory progress in oncology, Nuvation Bio has received early FDA approval for a supplemental New Drug Application for its drug IBTROZI. The approval updates the clinical profile for patients with ROS1-positive non-small cell lung cancer (NSCLC), specifically reflecting a median duration of response of nearly 50 months in TKI-naïve patients. This regulatory milestone was achieved four months ahead of the scheduled PDUFA action date.

The FDA's decision was supported by updated clinical data from the TRUST-I study, which demonstrated sustained efficacy without the emergence of new safety signals. According to company reports, the updated labeling strengthens the competitive positioning of IBTROZI in treating locally advanced or metastatic cases. This development is viewed as a positive catalyst for the company's clinical portfolio, validating the long-term benefits of its ROS1 inhibitor therapy.

Market data shows that NUVB shares stood at $5.78 at close on September 16, 2026, having traded within a range of $5.66 to $5.82 during that session. While the upcoming economic calendar does not list immediate catalysts for the biotech sector in the next week, the early approval serves as a key fundamental update for shareholders monitoring the commercial and clinical trajectory of the IBTROZI franchise.